Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8UMG

Chromodomains of human CHD1 complexed with UNC10142

Summary for 8UMG
Entry DOI10.2210/pdb8umg/pdb
DescriptorChromodomain-helicase-DNA-binding protein 1, 1-{4-[{2-(azonan-1-yl)-6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl}(methyl)amino]piperidin-1-yl}ethan-1-one, CHLORIDE ION, ... (4 entities in total)
Functional Keywordschd1, chromodomain-helicase dna-binding 1, methyllysine reader, peptide binding protein
Biological sourceHomo sapiens (human)
Total number of polymer chains3
Total formula weight67672.80
Authors
Graboski, A.L.,Redinbo, M.R. (deposition date: 2023-10-17, release date: 2024-10-23, Last modification date: 2025-11-05)
Primary citationJohnson, R.L.,Graboski, A.L.,Li, F.,Norris-Drouin, J.L.,Walton, W.G.,Arrowsmith, C.H.,Redinbo, M.R.,Frye, S.V.,James, L.I.
Discovery of CHD1 Antagonists for PTEN-Deficient Prostate Cancer.
J.Med.Chem., 67:20056-20075, 2024
Cited by
PubMed Abstract: CHD1 is a chromodomain-helicase DNA-binding protein that preferentially recognizes di- and trimethylated lysine 4 on histone H3 (H3K4me2/3). Genetic studies have established CHD1 as a synthetic lethal target in phosphatase and tensin homologue (PTEN)-deficient cancers. Despite this attractive therapeutic link, no inhibitors or antagonists of CHD1 have been reported to date. Herein, we report the discovery of UNC10142, a first-in-class small molecule antagonist of the tandem chromodomains of CHD1 that binds with an IC of 1.7 ± 0.2 μM. A cocrystal structure revealed a unique binding mode and competition pull-down experiments in cell lysates confirmed endogenous target engagement. Treatment of PTEN-deficient prostate cancer cells with UNC10142 led to a dose-dependent reduction in viability while PTEN-intact prostate cancer cells were unaffected, phenocopying genetic loss of CHD1. Overall, this study demonstrates the ligandability of the CHD1 chromodomains and suggests more potent and selective antagonists could translate to compounds of therapeutic value in PTEN-deficient cancers.
PubMed: 39508435
DOI: 10.1021/acs.jmedchem.4c01172
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.1 Å)
Structure validation

248335

PDB entries from 2026-01-28

PDB statisticsPDBj update infoContact PDBjnumon